CA2270913A1 - Human tumor necrosis factor receptor-like 2 - Google Patents
Human tumor necrosis factor receptor-like 2Info
- Publication number
- CA2270913A1 CA2270913A1 CA002270913A CA2270913A CA2270913A1 CA 2270913 A1 CA2270913 A1 CA 2270913A1 CA 002270913 A CA002270913 A CA 002270913A CA 2270913 A CA2270913 A CA 2270913A CA 2270913 A1 CA2270913 A1 CA 2270913A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- seq
- acid sequence
- polypeptide
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity.
Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
Claims (26)
1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
(a) a nucleotide sequence encoding the TR2 receptor having the amino acid sequence at positions from about -36 to about 247 in SEQ ID
NO:2;
(b) a nucleotide sequence encoding the TR2 receptor polypeptide having the amino acid sequence at positions from about -35 to about 247 in SEQ ID NO:2;
(c) a nucleotide sequence encoding the TR2 receptor polypeptide having the amino acid sequence at positions from about 1 to about 247 in SEQ ID NO:2;
(d) a nucleotide sequence encoding the TR2 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 97059;
(e) a nucleotide sequence encoding the mature TR2 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC
Deposit Number 97059;
(f) a nucleotide sequence encoding the TR2 extracellular domain;
(g) a nucleotide sequence encoding the TR2 transmembrane domain;
(h) a nucleotide sequence encoding the TR2 intracellular domain;
(i) a nucleotide sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about -36 to about 149 in SEQ
ID NO:5;
(j) a nucleotide sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about -35 to about 149 in SEQ
ID NO:5;
(k) a nucleotide sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about 1 to about 149 in SEQ
ID
NO:5;
(l) a nucleotide sequence encoding the TR2-SV1 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC
Deposit Number 97058;
(m) a nucleotide sequence encoding the mature TR2-SV1 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 97058;
(n) a nucleotide sequence encoding the TR2-SV2 receptor having the amino acid sequence in SEQ ID NO:8;
(o) a nucleotide sequence encoding the TR2-SV2 receptor having the amino acid sequence at positions from about 2 to about 136 in SEQ
ID
NO:8;
(p) a nucleotide sequence encoding the TR2-SV2 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC
Deposit Number 97057; and (q) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o) or (p).
(a) a nucleotide sequence encoding the TR2 receptor having the amino acid sequence at positions from about -36 to about 247 in SEQ ID
NO:2;
(b) a nucleotide sequence encoding the TR2 receptor polypeptide having the amino acid sequence at positions from about -35 to about 247 in SEQ ID NO:2;
(c) a nucleotide sequence encoding the TR2 receptor polypeptide having the amino acid sequence at positions from about 1 to about 247 in SEQ ID NO:2;
(d) a nucleotide sequence encoding the TR2 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 97059;
(e) a nucleotide sequence encoding the mature TR2 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC
Deposit Number 97059;
(f) a nucleotide sequence encoding the TR2 extracellular domain;
(g) a nucleotide sequence encoding the TR2 transmembrane domain;
(h) a nucleotide sequence encoding the TR2 intracellular domain;
(i) a nucleotide sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about -36 to about 149 in SEQ
ID NO:5;
(j) a nucleotide sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about -35 to about 149 in SEQ
ID NO:5;
(k) a nucleotide sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about 1 to about 149 in SEQ
ID
NO:5;
(l) a nucleotide sequence encoding the TR2-SV1 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC
Deposit Number 97058;
(m) a nucleotide sequence encoding the mature TR2-SV1 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 97058;
(n) a nucleotide sequence encoding the TR2-SV2 receptor having the amino acid sequence in SEQ ID NO:8;
(o) a nucleotide sequence encoding the TR2-SV2 receptor having the amino acid sequence at positions from about 2 to about 136 in SEQ
ID
NO:8;
(p) a nucleotide sequence encoding the TR2-SV2 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC
Deposit Number 97057; and (q) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o) or (p).
2. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in SEQ ID NO:1, SEQ ID NO:4 or SEQ ID NO:7.
3. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in SEQ ID NO:1 encoding a polypeptide having the amino acid sequence in SEQ ID NO:2, the nucleotide sequence in SEQ ID NO:4 encoding a polypeptide having the amino acid sequence in SEQ ID NO:5, or the nucleotide sequence in SEQ ID NO:7 encoding a polypeptide having the amino acid sequence in SEQ ID NO:8.
4. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in SEQ ID NO:1 encoding the mature TR2 receptor having the amino acid sequence in SEQ ID NO:2 or the nucleotide sequence in SEQ ID NO:4 encoding the mature TR2-SV1 receptor having the amino acid sequence in SEQ ID NO:5.
5. The nucleic acid molecule of claim 1 wherein said polynucleotide has the complete nucleotide sequence of the cDNA clone contained in any one of ATCC Deposit Numbers 97059, 97058 or 97057.
6. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding TR2 receptors having the amino acid sequence encoded by the cDNA clone contained in any one of ATCC Deposit Numbers 97059, 97058 or 97057.
7. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding mature TR2 receptors having the amino acid sequence encoded by the cDNA clone contained in any one of ATCC Deposit Numbers 97059 or 97058.
8. An isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), (c), (d), (e), (f), (g), (h), (i)) (j), (k), (l), (m), (n), (o), (p) or (q) of claim 1 wherein said polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A
residues or of only T residues.
residues or of only T residues.
9. An isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of a TR2 receptor having an amino acid sequence in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p) or (q) of claim 1.
10. The isolated nucleic acid molecule of claim 9, which encodes an epitope-bearing portion of a TR2 receptor selected from the group consisting of a polypeptide comprising amino acid residues from about 3 to about 34 in SEQ
ID NO:2; a polypeptide comprising amino acid residues from about 70 to about 84 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 106 to about 153 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 240 to about 247 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 3 to about 34 in SEQ ID NO:5; a polypeptide comprising amino acid residues from about 63 to about 100 in SEQ ID NO:5; a polypeptide comprising amino acid residues from about 135 to about 149 in SEQ ID NO:5;
a polypeptide comprising amino acid residues from about 56 to about 68 in SEQ
ID NO:8; and a polypeptide comprising amino acid residues from about 93 to about 136 in SEQ ID NO:8.
ID NO:2; a polypeptide comprising amino acid residues from about 70 to about 84 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 106 to about 153 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 240 to about 247 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 3 to about 34 in SEQ ID NO:5; a polypeptide comprising amino acid residues from about 63 to about 100 in SEQ ID NO:5; a polypeptide comprising amino acid residues from about 135 to about 149 in SEQ ID NO:5;
a polypeptide comprising amino acid residues from about 56 to about 68 in SEQ
ID NO:8; and a polypeptide comprising amino acid residues from about 93 to about 136 in SEQ ID NO:8.
11. The isolated nucleic acid molecule of claim 1, which encodes a TR2 receptor extracellular domain.
12. The isolated nucleic acid molecule of claim 1, which encodes a TR2 receptor transmembrane domain.
13. The isolated nucleic acid molecule of claim 1, which encodes a TR2 receptor intracellular domain.
14. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.
15. A recombinant vector produced by the method of claim 14.
16. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 15 into a host cell.
17. A recombinant host cell produced by the method of claim 16.
18. A recombinant method for producing a TR2 polypeptide, comprising culturing the recombinant host cell of claim 17 under conditions such that said polypeptide is expressed and recovering said polypeptide.
19. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence in SEQ ID NO:1 wherein nucleotide 314 is either guanine or adenine, nucleotide 386 is either thymine or cytosine, and nucleotide 627 is either thymine or cytosine.
20. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence encoding the TR2 receptor having the amino acid sequence in SEQ ID NO:2 wherein amino acid number -20 is either lysine or arginine and amino acid number 5 is either serine or phenylalanine.
21. An isolated TR2 polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
(a) the amino acid sequence of the TR2 polypeptide having the amino acid sequence at positions from about -36 to about 247 in SEQ ID NO:2;
(b) the amino acid sequence of the TR2 polypeptide having the amino acid sequence at positions from about -35 to about 247 in SEQ ID NO:2;
(c) the amino acid sequence of the TR2 polypeptide having the amino acid sequence at positions from about 1 to about 247 in SEQ ID NO:2;
(d) the amino acid sequence of the TR2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 97059;
(e) the amino acid sequence of the mature TR2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC
Deposit Number 97059;
(f) the amino acid sequence of the TR2 receptor extracellular domain;
(g) the amino acid sequence of the TR2 receptor transmembrane domain;
(h) the amino acid sequence of the TR2 receptor intracellular domain;
(i) the amino acid sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about-36 to about 149 in SEQ
ID NO:5;
(j) the amino acid sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about -35 to about 149 in SEQ
ID NO:5;
(k) the amino acid sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about 1 to about 149 in SEQ
ID
NO:5;
(l) the amino acid sequence encoding the TR2-SV1 receptor having the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 97058;
(m) the amino acid sequence encoding the mature TR2-SV1 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 97058;
(n) the amino acid sequence encoding the TR2-SV2 receptor having the amino acid sequence in SEQ ID NO:8;
(o) the amino acid sequence encoding the TR2-SV2 receptor having the amino acid sequence at positions from about 2 to about 136 in SEQ
ID
NO:8;
(p) the amino acid sequence encoding the TR2-SV2 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC
Deposit Number 97057; and (q) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o) or (p).
(a) the amino acid sequence of the TR2 polypeptide having the amino acid sequence at positions from about -36 to about 247 in SEQ ID NO:2;
(b) the amino acid sequence of the TR2 polypeptide having the amino acid sequence at positions from about -35 to about 247 in SEQ ID NO:2;
(c) the amino acid sequence of the TR2 polypeptide having the amino acid sequence at positions from about 1 to about 247 in SEQ ID NO:2;
(d) the amino acid sequence of the TR2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 97059;
(e) the amino acid sequence of the mature TR2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC
Deposit Number 97059;
(f) the amino acid sequence of the TR2 receptor extracellular domain;
(g) the amino acid sequence of the TR2 receptor transmembrane domain;
(h) the amino acid sequence of the TR2 receptor intracellular domain;
(i) the amino acid sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about-36 to about 149 in SEQ
ID NO:5;
(j) the amino acid sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about -35 to about 149 in SEQ
ID NO:5;
(k) the amino acid sequence encoding the TR2-SV1 receptor having the amino acid sequence at positions from about 1 to about 149 in SEQ
ID
NO:5;
(l) the amino acid sequence encoding the TR2-SV1 receptor having the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 97058;
(m) the amino acid sequence encoding the mature TR2-SV1 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 97058;
(n) the amino acid sequence encoding the TR2-SV2 receptor having the amino acid sequence in SEQ ID NO:8;
(o) the amino acid sequence encoding the TR2-SV2 receptor having the amino acid sequence at positions from about 2 to about 136 in SEQ
ID
NO:8;
(p) the amino acid sequence encoding the TR2-SV2 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC
Deposit Number 97057; and (q) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o) or (p).
22. An isolated polypeptide comprising an epitope-bearing portion of a TR2 receptor protein, wherein said portion is selected from the group consisting of: a polypeptide comprising amino acid residues from about 3 to about 34 in SEQ
ID NO:2; a polypeptide comprising amino acid residues from about 70 to about 84 in SEQ ID NO;2; a polypeptide comprising amino acid residues from about 106 to about 153 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 240 to about 247 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 3 to about 34 in SEQ ID NO:5; a polypeptide comprising amino acid residues from about 63 to about 100 in SEQ ID NO:5; a polypeptide comprising amino acid residues from about 135 to about 149 in SEQ ID NO:5;
a polypeptide comprising amino acid residues from about 56 to about 68 in SEQ
117 NO:8; or a polypeptide comprising amino acid residues from about 93 to about 136 in SEQ ID NO:8.
ID NO:2; a polypeptide comprising amino acid residues from about 70 to about 84 in SEQ ID NO;2; a polypeptide comprising amino acid residues from about 106 to about 153 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 240 to about 247 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 3 to about 34 in SEQ ID NO:5; a polypeptide comprising amino acid residues from about 63 to about 100 in SEQ ID NO:5; a polypeptide comprising amino acid residues from about 135 to about 149 in SEQ ID NO:5;
a polypeptide comprising amino acid residues from about 56 to about 68 in SEQ
117 NO:8; or a polypeptide comprising amino acid residues from about 93 to about 136 in SEQ ID NO:8.
23. An isolated antibody that binds specifically to a TR2 receptor polypeptide of claim 21.
24. A method of treating herpes simplex viral infection comprising introducing an effective amount of a soluble fragment of a TR2 polypeptide into an individual to be treated in admixture with a pharmaceutically acceptable carrier.
25. A method of treating a disease state associated with aberrant cell survival comprising introducing an effective amount of a TR2 protein, or agonist or antagonist thereof, into an individual to be treated in admixture with a pharmaceutically acceptable carrier.
26. A method of screening for agonists and antagonists of TR2 activity comprising:
(a) contacting cells which express TR2 polypeptides with a candidate compound, (b) assaying a cellular response, and (c) comparing the cellular response to a standard cellular response made in absence of the candidate compound; whereby, an increased cellular response over the standard indicates that the compound is an agonist and a decreased cellular response over the standard indicates that the compound is an antagonist.
(a) contacting cells which express TR2 polypeptides with a candidate compound, (b) assaying a cellular response, and (c) comparing the cellular response to a standard cellular response made in absence of the candidate compound; whereby, an increased cellular response over the standard indicates that the compound is an agonist and a decreased cellular response over the standard indicates that the compound is an antagonist.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1996/018540 WO1998018824A1 (en) | 1996-10-30 | 1996-10-30 | Human tumor necrosis factor receptor-like 2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2270913A1 true CA2270913A1 (en) | 1998-05-07 |
| CA2270913C CA2270913C (en) | 2011-05-24 |
Family
ID=22256163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2270913A Expired - Fee Related CA2270913C (en) | 1996-10-30 | 1996-10-30 | Human tumor necrosis factor receptor-like 2 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0961782A4 (en) |
| JP (1) | JP2001502912A (en) |
| CA (1) | CA2270913C (en) |
| WO (1) | WO1998018824A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7427492B1 (en) | 1995-06-05 | 2008-09-23 | Human Genome Sciences, Inc. | Polynucleotides encoding human tumor necrosis factor receptor-like2 |
| US6291207B1 (en) | 1995-07-28 | 2001-09-18 | Northwestern University | Herpes virus entry receptor protein |
| US6998108B1 (en) | 1997-07-07 | 2006-02-14 | La Jolla Institute For Allergy And Immunology | Antibodies to p30 polypeptides and methods making and using same |
| US7118742B2 (en) | 1997-07-07 | 2006-10-10 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| US6140467A (en) * | 1997-07-07 | 2000-10-31 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| US6346388B1 (en) | 1997-08-13 | 2002-02-12 | Smithkline Beecham Corporation | Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2 |
| US6287808B1 (en) | 1998-09-03 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Molecules of the herpesvirus-entry-mediator-related protein family and uses thereof |
| JP2002529051A (en) * | 1998-09-03 | 2002-09-10 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Novel molecules of the herpesvirus entry mediator-related protein family and uses thereof |
| TR200504220T2 (en) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins. |
| US7148061B2 (en) | 2000-02-11 | 2006-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| WO2001079496A2 (en) * | 2000-03-13 | 2001-10-25 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| AU5338701A (en) * | 2000-04-12 | 2001-10-30 | Jolla Inst Allergy Immunolog | Ligand for herpes simplex virus entry mediator and methods of use |
| US20040235173A1 (en) * | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0393438T3 (en) * | 1989-04-21 | 2005-05-30 | Amgen Inc | TNF receptor, TNF binding proteins and DNAs encoding it |
| US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| US5464938A (en) * | 1990-04-09 | 1995-11-07 | Immunex Corporation | Isolated viral protein TNF antagonists |
| EP0822984A4 (en) * | 1995-04-27 | 2000-05-03 | Human Genome Sciences Inc | Human tumor necrosis factor receptors |
-
1996
- 1996-10-30 WO PCT/US1996/018540 patent/WO1998018824A1/en not_active Application Discontinuation
- 1996-10-30 EP EP96942776A patent/EP0961782A4/en not_active Withdrawn
- 1996-10-30 JP JP10520413A patent/JP2001502912A/en not_active Ceased
- 1996-10-30 CA CA2270913A patent/CA2270913C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0961782A4 (en) | 2003-07-16 |
| WO1998018824A9 (en) | 1999-09-30 |
| WO1998018824A1 (en) | 1998-05-07 |
| EP0961782A1 (en) | 1999-12-08 |
| CA2270913C (en) | 2011-05-24 |
| JP2001502912A (en) | 2001-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6844168B1 (en) | Compositions comprising polynucleotides encoding human fibroblast growth factor receptor and uses thereof | |
| CA2343655A1 (en) | Interleukin 17-like receptor protein | |
| WO1992014748A1 (en) | Identification of a novel human receptor tyrosine kinase gene | |
| CA2270913A1 (en) | Human tumor necrosis factor receptor-like 2 | |
| George Jr et al. | Genomic organization of the human skeletal muscle sodium channel gene | |
| AU7608898A (en) | Ntn-2 member of tnf ligand family | |
| WO2004096980A2 (en) | Novel polynucleotides encoding soluble polypeptides and methods using same | |
| JP2002522041A5 (en) | ||
| CA2321089A1 (en) | Human homolog of the drosophila protein "fused" | |
| CA2329054A1 (en) | A novel polypeptide hormone phosphatonin | |
| CA2323776A1 (en) | Cytokine receptor common gamma chain like | |
| CA2302808A1 (en) | 50 human secreted proteins | |
| JP2003525566A (en) | 125 human secreted proteins | |
| US20020160451A1 (en) | Novel orphan receptors | |
| JP2000510690A (en) | Mammalian mixed lymphocyte receptor, chemokine receptor (MMLR-CCR) | |
| AU628895B2 (en) | Cloning and expression of a protein which modulates cellular response to type i interferon | |
| AU663216B2 (en) | Bone-related cadherin-like protein and process for its production | |
| CA2241786A1 (en) | Novel amp activated protein kinase | |
| AU748167B2 (en) | Novel nucleic acid and polypeptide | |
| CN101309930A (en) | Splice variants of erbb ligands, compositions and uses thereof | |
| US6384205B1 (en) | Metabotropic glutamate receptor 4 nucleic acid | |
| AU753400C (en) | Orphan receptors | |
| WO1998022586A2 (en) | HUMAN POLYHOMEOTIC 2 (hph2) ACTS AS A TUMOR SUPPRESSOR | |
| US6207413B1 (en) | Nucleic acids encoding novel orphan cytokine receptors | |
| CA2236001C (en) | Biologically active eph family ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20151030 |